Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission
- PMID: 21521323
- DOI: 10.1111/j.1365-2265.2011.04055.x
Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission
Abstract
Objective: Cushing's syndrome is associated with several comorbidities responsible for the increased cardiovascular risk, not only during the active phase but also after disease remission.
Design: In 29 patients with Cushing's syndrome (14 Cushing's diseases and 15 adrenal adenomas), waist circumference, fasting and 2-h glucose after oral glucose tolerance test (OGTT), lipid profile and blood pressure were evaluated during the active disease and 1 year after remission and compared with those in 29 sex-, age- and BMI-matched controls.
Results: During the active disease, waist circumference, 2-h glucose after OGTT, total and LDL cholesterol were higher in patients with Cushing's syndrome than in controls (P < 0·001) but similar in Cushing's disease and adrenal adenomas. The prevalence of impaired glucose tolerance (IGT), diabetes mellitus, dyslipidaemia and hypertension was higher (P < 0·001) in patients with Cushing's syndrome (27%, 24%, 59% and 72%) than in controls (10%, 0%, 21% and 10%), with no significant difference between Cushing's disease and adrenal adenomas. One year following hormonal remission, waist circumference persisted higher than in controls (P < 0·05) in both Cushing's disease and adrenal adenomas. Metabolic and cardiovascular abnormalities were still present in both groups, although with a lower prevalence, as well as with a more marked decrease in adrenal adenomas (P < 0·05 vs active disease for IGT, dyslipidaemia and hypertension).
Conclusions: These results show that chronic hypercortisolism, independently of its aetiology, contributes to metabolic impairment and increased cardiovascular risk, while these abnormalities mostly persist in patients with previous Cushing's disease after hormonal remission. Pituitary hormonal deficiencies, hormonal replacement treatments and/or incomplete cure from Cushing's disease may account for these findings.
© 2011 Blackwell Publishing Ltd.
Similar articles
-
Circadian blood pressure profile in patients with active Cushing's disease and after long-term cure.Horm Metab Res. 2007 Dec;39(12):908-14. doi: 10.1055/s-2007-992813. Epub 2007 Nov 28. Horm Metab Res. 2007. PMID: 18046661
-
Early post-operative ACTH and cortisol as predictors of remission in Cushing's disease.Acta Neurochir (Wien). 2007;149(5):471-7; discussion 477-9. doi: 10.1007/s00701-007-1133-1. Epub 2007 Apr 5. Acta Neurochir (Wien). 2007. PMID: 17406780
-
Increased risk of unfavorable metabolic outcome during short-term follow-up in subjects with nonfunctioning adrenal adenomas.Med Princ Pract. 2012;21(5):429-34. doi: 10.1159/000336589. Epub 2012 Mar 2. Med Princ Pract. 2012. PMID: 22398948
-
Genetics of Cushing's syndrome.Neuroendocrinology. 2010;92 Suppl 1:6-10. doi: 10.1159/000314215. Epub 2010 Sep 10. Neuroendocrinology. 2010. PMID: 20829611 Review.
-
The metabolic syndrome and cardiovascular risk in Cushing's syndrome.Endocrinol Metab Clin North Am. 2005 Jun;34(2):327-39, viii. doi: 10.1016/j.ecl.2005.01.010. Endocrinol Metab Clin North Am. 2005. PMID: 15850845 Review.
Cited by
-
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31. doi: 10.1210/jc.2015-1818. Epub 2015 Jul 29. J Clin Endocrinol Metab. 2015. PMID: 26222757 Free PMC article.
-
Cardiovascular risk improvement after laparoscopic adrenalectomy in patients with cortisol-secreting adrenal adenoma, a retrospective cohort study.Gland Surg. 2024 Nov 30;13(11):2128-2136. doi: 10.21037/gs-24-398. Epub 2024 Nov 26. Gland Surg. 2024. PMID: 39678424 Free PMC article.
-
Consensus on diagnosis and management of Cushing's disease: a guideline update.Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20. Lancet Diabetes Endocrinol. 2021. PMID: 34687601 Free PMC article. Review.
-
Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.J Endocrinol Invest. 2016 Feb;39(2):235-55. doi: 10.1007/s40618-015-0404-6. Epub 2015 Dec 30. J Endocrinol Invest. 2016. PMID: 26718207
-
Weight gain reversibility and BMI following treatment for Cushing's syndrome: long-term outcomes and potential predictors.Pituitary. 2025 Jun 26;28(4):78. doi: 10.1007/s11102-025-01550-z. Pituitary. 2025. PMID: 40569537
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources